latest update:
[TrialBase DB]

trial summary · NCT07903623

QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia

A Prospective, Single-Arm, Single-Center Clinical Study of QLS4131 Combined With Isatuximab in Patients With Newly Diagnosed Primary Plasma Cell Leukemia

Trial record from the TrialBase DB dataset, status RECRUITING, condition Primary Plasma Cell Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07903623phase PHASE2enrollment 15start 2026-10-25

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this clinical trial is to learn whether QLS4131, a BCMA/GPRC5D/CD3 trispecific antibody, can improve treatment outcomes when combined with isatuximab in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate the safety of this treatment combination. The main questions it aims to answer are: * How many participants achieve measurable residual disease (MRD) negativity after 9 treatment cycles? * What side effects occur during treatment with QLS4131 combined with isatuximab? * How many participants respond to treatment, and how many achieve a complete response? * How many participants achieve sustained MRD negativity? * How long do participants remain free from disease progression, and how long do they survive after starting treatment? All participants will receive the study treatment. There is no comparison group in this study. Participants will: * Receive QLS4131 by subcutaneous injection together with intravenous isatuximab in 28-day treatment cycles. * Undergo regular blood tests, bone marrow examinations, and disease assessments to monitor treatment response and safety. * Undergo peripheral blood stem cell mobilization and collection after the first 3 treatment cycles, if appropriate. * Be monitored throughout the study for side effects, including adverse events and serious adverse events.

Source record: https://clinicaltrials.gov/study/NCT07903623

Facts

registry idNCT07903623
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionPrimary Plasma Cell Leukemia
sponsorInstitute of Hematology & Blood Diseases Hospital, China
sponsor classOTHER
enrollment15
start date2026-10-25
primary completion2029-12-30
completion2031-12-30
results postednot reported

Conditions

  • Primary Plasma Cell Leukemia

Interventions

  • QLS4131
  • Isatuximab

Countries

  • China

Intervention types: DRUG

Work with this record